or Try an Advanced Search...

    Technical Analysis for SYRE - Spyre Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 27.14 -1.33% -0.37
    SYRE closed up 2.23 percent on Wednesday, November 20, 2024, on 2.12 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical SYRE trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup -1.33%
    Calm After Storm Range Contraction -1.33%
    NR7 Range Contraction -1.33%
    Lower Bollinger Band Walk Weakness -1.33%
    Wide Bands Range Expansion -1.33%
    Oversold Stochastic Weakness -1.33%
    MACD Bearish Centerline Cross Bearish 0.87%
    Volume Surge Other 0.87%
    Calm After Storm Range Contraction 0.87%
    Lower Bollinger Band Walk Weakness 0.87%
    Older End-of-Day Signals for SYRE ...

       Recent Intraday Alerts

    Alert Time
    Outside Day about 1 hour ago
    Slingshot Bearish Entry about 1 hour ago
    Fell Below Previous Day's Low about 1 hour ago
    Down 2 % about 1 hour ago
    Down 1% about 1 hour ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SYRE Chart by TradingView
    Basic chart:

    Profile

    Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immunology Autoimmune Disease Antibodies Monoclonal Antibody Antibody Inflammatory Bowel Disease

    Is SYRE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Spyre Therapeutics announces pricing of $200 million public offering of common stock
    Nov 19 Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
    Nov 18 Spyre Therapeutics announces proposed secondary offering
    Nov 18 Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
    Nov 12 Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potentia...
    Nov 11 Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
    Nov 8 Spyre Therapeutics GAAP EPS of -$1.36
    Nov 7 Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Oct 30 Spyre Therapeutics to Participate in Upcoming November Investor Conferences
    Oct 14 Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
    See more SYRE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 47.97
    52 Week Low 10.42
    Average Volume 588,585
    200-Day Moving Average 31.26
    50-Day Moving Average 31.28
    20-Day Moving Average 33.74
    10-Day Moving Average 32.90
    Average True Range 2.40
    RSI (14) 35.06
    ADX 30.01
    +DI 16.00
    -DI 40.20
    Chandelier Exit (Long, 3 ATRs) 33.05
    Chandelier Exit (Short, 3 ATRs) 32.95
    Upper Bollinger Bands 40.79
    Lower Bollinger Band 26.70
    Percent B (%b) 0.06
    BandWidth 41.75
    MACD Line -0.74
    MACD Signal Line 0.54
    MACD Histogram -1.282
    Fundamentals Value
    Market Cap 990.58 Million
    Num Shares 36 Million
    EPS
    Price-to-Sales 939.83
    Price-to-Book 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 30.01
    Resistance 3 (R3) 30.05 29.27 29.59
    Resistance 2 (R2) 29.27 28.63 29.24 29.45
    Resistance 1 (R1) 28.38 28.23 28.83 28.34 29.31
    Pivot Point 27.60 27.60 27.82 27.57 27.60
    Support 1 (S1) 26.71 26.96 27.16 26.67 25.69
    Support 2 (S2) 25.93 26.56 25.90 25.55
    Support 3 (S3) 25.04 25.93 25.41
    Support 4 (S4) 25.00